Skip to Content
Merck
  • Involvement of renal sympathetic nerve overactivation in the progression of chronic kidney disease in rats.

Involvement of renal sympathetic nerve overactivation in the progression of chronic kidney disease in rats.

Journal of cardiovascular pharmacology (2013-10-03)
Shuhei Kobuchi, Ryosuke Tanaka, Asami Funai, Rie Suzuki, Maki Yazawa, Hidenobu Tsutsui, Mamoru Ohkita, Kazuhide Ayajiki, Yasuo Matsumura
ABSTRACT

Time-dependent changes in the renal sympathetic nerve activity (RSNA) in the progression of chronic kidney disease (CKD) have not been investigated, despite the fact that renal sympathetic nervous system is augmented in the condition of CKD. In the present study, we examined time-dependent changes in RSNA and renal venous norepinephrine concentrations for 12 weeks using 5 of 6 nephrectomized CKD rats. Both RSNA and norepinephrine concentrations were increased during the early phase in the progression of CKD. Urinary protein excretion and systolic blood pressure (SBP) were gradually increased during 12 weeks after 5 of 6 nephrectomy. Treatment with γ-aminobutyric acid or the combination of prazosin and propranolol in the early phase (0-4 weeks) after 5 of 6 nephrectomy significantly attenuated the increases in urinary protein excretion and SBP in 5 of 6 nephrectomized rats. On the other hand, the same treatment in the late phase (8-12 weeks) after 5 of 6 nephrectomy failed to suppress the proteinuria and increase in SBP. Treatment with hydralazine at hypotensive dose for 12 weeks also failed to affect the proteinuria in 5 of 6 nephrectomized CKD rats. In conclusion, the augmentation of renal sympathetic nervous system in early phase after 5 of 6 nephrectomy is closely related to the development of partial ablation-induced CKD in rats.

MATERIALS
Product Number
Brand
Product Description

Propranolol hydrochloride, European Pharmacopoeia (EP) Reference Standard
Supelco
Propranolol hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Propranolol hydrochloride, United States Pharmacopeia (USP) Reference Standard
USP
Prazosin hydrochloride, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Prazosin hydrochloride, ≥99.0% (HPLC)
Sigma-Aldrich
(±)-Propranolol hydrochloride, ≥99% (TLC), powder
Sigma-Aldrich
Hexamethonium bromide
Supelco
(±)-Propranolol hydrochloride, analytical standard
Prazosin hydrochloride, European Pharmacopoeia (EP) Reference Standard